Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Jörg Mahlich"'
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
When assessing the value of new drugs regulatory authorities across the world frequently make different decisions even though their decisions are based on the same evidence package. In this perspective we argue that even in today’s world regulatory
Externí odkaz:
https://doaj.org/article/84bdb86d673745eeb62757db92c3bbd1
Autor:
Peter Borchmann, Jan-Michel Heger, Jörg Mahlich, Michael S. Papadimitrious, Sybille Riou, Barbara Werner
Publikováno v:
Oncology and Therapy, Vol 11, Iss 1, Pp 65-81 (2022)
Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma with increasing prevalence. Although the disease burden associated with DLBCL is high, only limited data on healthcare resource utilizatio
Externí odkaz:
https://doaj.org/article/e1af2827b12741ddad002a14c983e08b
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 2, Pp 976-982 (2022)
Background The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis. Objective The objective of this study was to examine the cost per responder of guselkumab compared with other t
Externí odkaz:
https://doaj.org/article/6f9e92942dd24e0da77e65fe0f933957
Publikováno v:
Health Economics Review, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Aim The productivity of pharmaceutical research and development (R&D) investments is declining due to high failure rates in clinical research. Recently, the US Food and Drug Administration (FDA) acknowledged that adaptive designs can make dr
Externí odkaz:
https://doaj.org/article/277c7a064aa94635afd7778b22dc3233
Autor:
Yoji Inoue, Shinichi Oka, Seiji Yokoyama, Koichi Hasegawa, Jörg Mahlich, Ulrike Schaede, Noriyuki Habuka, Yoko Murata
Publikováno v:
Healthcare, Vol 11, Iss 4, p 451 (2023)
Long-term medical care for people living with HIV (PLHIV) is critical for treatment efficacy, and various studies have examined reasons for antiretroviral therapy (ART) non-adherence. In Japan, doctors assume patients maintain high adherence. However
Externí odkaz:
https://doaj.org/article/ae33c081e742437a97fe6f7621d6f982
Publikováno v:
Neurology and Therapy, Vol 8, Iss 2, Pp 433-447 (2019)
Abstract Introduction The Japanese government’s current policy is to encourage hospitals to discharge hospital patients with schizophrenia earlier and provide them with community care. This study aims to analyze clinical and economic outcomes of di
Externí odkaz:
https://doaj.org/article/f98967b6e8c14077a68edda41eb8fdfc
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 2, Pp 269-283 (2019)
Abstract Introduction We have developed a new framework to assess shared decision-making (SDM) as a tool to improve patient satisfaction. This framework is based on a “preference fit” index that relates SDM to patient treatment preferences and pa
Externí odkaz:
https://doaj.org/article/ed85670185694181ad240d74db780f50
Autor:
Jörg Mahlich, Rosarin Sruamsiri
Publikováno v:
International Journal for Equity in Health, Vol 18, Iss 1, Pp 1-11 (2019)
Abstract Background Co-insurance rates in Japan decrease when patients turn 70 years of age. We aim to compare changes in medical demand for Japanese patients with rheumatoid arthritis (RA) at age 70 prior to 2014, when there was a reduction in co-in
Externí odkaz:
https://doaj.org/article/88fd53459f3f411391971a9da33aa25f
Publikováno v:
BMC Gastroenterology, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese
Externí odkaz:
https://doaj.org/article/abb2ea0bb39e44b98c97539482409ae8
Autor:
Jörg Mahlich, Srirangan Dheban
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
It is widely acknowledged that using p-value thresholds as the basis for making decision on health care spending is not appropriate. In the context of medical decision making, we argue that patient preferences need to be a stronger factor. Depending
Externí odkaz:
https://doaj.org/article/845d9b367d16400d91b2ac4e0018cb66